Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25265923 | 1.00 | SHBG (0.38) | SHBGALDH1A1THRBRECQLEPHX2 | |
| SCHEMBL3394270 | 0.90 | — | — | |
| SCHEMBL10442249 | 0.80 | EPHX1 (0.41) | ALDH1A1THRBRECQLEPHX2CYP2C19 | |
| SCHEMBL4015606 | 0.78 | EPHX1 (0.44) | ALDH1A1THRBRECQLEPHX2CYP2C19 | |
| SCHEMBL4957639 | 0.78 | EPHX1 (0.44) | ALDH1A1THRBRECQLEPHX2CYP2C19 | |
| SCHEMBL4422113 | 0.78 | EPHX1 (0.44) | ALDH1A1THRBRECQLEPHX2CYP2C19 | |
| SCHEMBL7766019 | 0.75 | SHBG (0.41) | SHBGEPHX2DPP4DPP7DPP8 | |
| SCHEMBL2238242 | 0.74 | ALDH1A1 (0.33) | ALDH1A1THRBRECQLCYP2C19 | |
| SCHEMBL5263851 | 0.74 | CPN1 (0.52) | ALDH1A1THRBRECQL | |
| SCHEMBL28305045 | 0.73 | SHBG (0.39) | SHBGEPHX2DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-115843297-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-4146649-A1 | COMPOUNDS AS BCL-2 INHIBITORS | Fochon Pharmaceuticals, Ltd. (CN) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | SHBG 2234/4885ALDH1A1 3019/4885THRB 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.